https://www.iccnconnect.com/ 2025-10-08T07:24:53+00:00 https://www.iccnconnect.com/t-dxd-plus-pertuzumab-receives-fda-approval-shifting-the-frontline-her2-positive-paradigm/ 2025-12-15T21:33:57+00:00 https://www.iccnconnect.com/fda-approves-niraparib-plus-abiraterone-acetate-and-prednisone-for-brca2-mutated-mcspc/ 2025-12-15T03:32:48+00:00 https://www.iccnconnect.com/fda-approves-durvalumab-for-resectable-gastric-and-gastroesophageal-junction-adenocarcinoma/ 2025-12-15T03:29:09+00:00 https://www.iccnconnect.com/fda-grants-traditional-approval-to-pirtobrutinib-jaypirca-for-cll-sll/ 2025-12-15T03:26:14+00:00 https://www.iccnconnect.com/enfortumab-vedotin-pembrolizumab-for-muscle-invasive-bladder-cancer-mibc/ 2025-11-22T03:34:23+00:00 https://www.iccnconnect.com/imdelltra-for-relapsed-extensive-stage-small-cell-lung-cancer/ 2025-11-20T02:19:23+00:00 https://www.iccnconnect.com/epcoritamab-bysp-for-follicular-lymphoma/ 2025-11-19T11:37:41+00:00 https://www.iccnconnect.com/ziftomenib-for-npm1-mutated-r-r-aml/ 2025-11-13T19:44:35+00:00 https://www.iccnconnect.com/fda-approves-blenrep-in-relapsed-refractory-multiple-myeloma/ 2025-11-11T13:22:43+00:00 https://www.iccnconnect.com/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma/ 2025-11-11T13:18:02+00:00 https://www.iccnconnect.com/oral-serd-fda-approval/ 2025-09-29T09:29:24+00:00 https://www.iccnconnect.com/new-approval-for-immune-thrombocytopenia-itp/ 2025-09-23T14:42:50+00:00 https://www.iccnconnect.com/aquila-study-shows-pfs-and-os-benefit-in-smoldering-myeloma/ 2025-09-14T21:39:15+00:00 https://www.iccnconnect.com/emerging-technologies-and-advances-in-precision-cancer-treatment-for-2025/ 2025-09-11T21:47:58+00:00 https://www.iccnconnect.com/adriatic-trial-sclc-maintenance-durvalumab-shows-2-year-improvement-in-os/ 2025-08-26T15:06:02+00:00 https://www.iccnconnect.com/myeloma-induction-can-ai-generate-a-treatment-algorithm/ 2025-08-21T20:48:13+00:00 https://www.iccnconnect.com/nrg-oncology-bn007-no-pfs-benefit-with-dual-immunotherapy-and-radiation-in-mgmt-unmethylated-gbm/ 2025-08-21T20:31:53+00:00 https://www.iccnconnect.com/keynote-689-perioperative-pembrolizumab-shows-efficacy-in-resectable-head-and-neck-cancer-patients-with-tumors-expressing-pdl1/ 2025-08-13T02:32:09+00:00 https://www.iccnconnect.com/head-and-neck-nivopostop-study-shows-efficacy-in-adjuvant-setting/ 2025-08-13T02:25:28+00:00 https://www.iccnconnect.com/augment-101-phase-i-ii-study-for-patients-with-kmt2ar-or-npm1-mutation-in-r-r-aml/ 2025-08-13T02:18:37+00:00 https://www.iccnconnect.com/soho-2025-meeting/ 2025-08-13T00:43:33+00:00 https://www.iccnconnect.com/front-line-therapy-for-metastatic-anal-scc/ 2025-08-13T00:15:29+00:00 https://www.iccnconnect.com/stride-in-hcc-5-year-follow-up-data/ 2025-08-11T22:20:37+00:00 https://www.iccnconnect.com/checkmate-9dw-dual-immunotherapy-in-front-line-hcc/ 2025-08-11T22:15:02+00:00 https://www.iccnconnect.com/leap-015-addition-of-lenvatinib-and-pembrolizumab-to-chemotherapy-shows-modest-improvement-in-pfs-in-advanced-esophageal-and-gej-cancers/ 2025-08-11T22:10:56+00:00 https://www.iccnconnect.com/phase-iii-rindberg-trial-no-impact-of-continuing-ramucirumab-beyond-2nd-line-in-gastric-and-gej-adenocarcinoma/ 2025-08-11T22:03:26+00:00 https://www.iccnconnect.com/perioperative-chemoimmunotherapy-bladder-cancer-phase-iii-niagara-trial/ 2025-08-11T21:55:21+00:00 https://www.iccnconnect.com/zongertinib-approved-for-her2-positive-mutations-in-nsclc/ 2025-08-11T21:48:42+00:00 https://www.iccnconnect.com/darolotamide-approval-for-mcspc/ 2025-08-11T02:46:31+00:00 https://www.iccnconnect.com/esmo-congress-2025/ 2025-08-11T02:38:09+00:00 https://www.iccnconnect.com/commands-trial-update/ 2025-08-11T02:10:19+00:00 https://www.iccnconnect.com/dellphi-304-tarlatamab-small-cell-lung-cancer/ 2025-08-11T01:34:36+00:00 https://www.iccnconnect.com/aegean-trial-perioperative-durvalumab-nsclc/ 2025-08-11T01:31:23+00:00 https://www.iccnconnect.com/phase-iii-mariposa-egfr-mutated-nsclc/ 2025-08-11T01:28:48+00:00 https://www.iccnconnect.com/flaura-2-osimertinib-with-chemotherapy/ 2025-08-11T01:26:41+00:00 https://www.iccnconnect.com/dreamm-8-study-myeloma-belantamab/ 2025-08-11T01:23:36+00:00 https://www.iccnconnect.com/atomic-trial-adjuvant-colon-cancer/ 2025-08-11T01:17:54+00:00 https://www.iccnconnect.com/phase-3-cabinet-neuroendocrine-tumors/ 2025-08-11T00:54:47+00:00 https://www.iccnconnect.com/phase-3-amplitude-study-prostate-cancer/ 2025-08-11T00:53:57+00:00 https://www.iccnconnect.com/phase-iii-serena-6-hr-breast-cancer/ 2025-08-11T00:53:00+00:00 https://www.iccnconnect.com/phase-iii-patina-study-hr-her2-breast-cancer/ 2025-08-11T00:52:05+00:00 https://www.iccnconnect.com/netter-2-efficacy-of-lu-dotatate-in-net/ 2025-08-10T14:44:55+00:00 https://www.iccnconnect.com/ash-2025-annual-meeting/ 2025-08-10T12:27:04+00:00 https://www.iccnconnect.com/relapsed-or-refractory-follicular-lymphoma-chemotherapy-free-option/ 2025-08-10T12:22:55+00:00 https://www.iccnconnect.com/bispecific-antibody-approval-for-relapsed-or-refractory-multiple-myeloma/ 2025-08-10T12:09:15+00:00 https://www.iccnconnect.com/potential-new-drug-for-pancreatic-cancer/ 2025-08-10T11:48:18+00:00 https://www.iccnconnect.com/gastric-gej-phase-iii-matterhorn/ 2025-07-28T22:51:34+00:00